{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:12:57Z","timestamp":1777425177406,"version":"3.51.4"},"reference-count":108,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2020,7,2]]},"DOI":"10.1080\/14728214.2020.1801632","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T10:07:38Z","timestamp":1595671658000},"page":"273-284","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Emerging drugs for the treatment of chronic pruritic diseases"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-7166","authenticated-orcid":false,"given":"Kayla","family":"Fourzali","sequence":"first","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel Shireen","family":"Golpanian","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2018.02.008"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.035"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.005"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.178"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.044"},{"issue":"11","key":"cit0006","first-page":"1085","volume":"99","author":"St\u00e4nder S","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12862"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2018.01.014"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15145"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.010"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3348"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1572"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14464"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1560267"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3164"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08941.x"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15450"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01900-5"},{"issue":"7","key":"cit0020","first-page":"750","volume":"17","author":"Zimmermann M","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1080\/00015550410023284"},{"key":"cit0022","author":"Hashimoto T","journal-title":"J Am Acad Dermatol"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2417"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15973"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8488-5"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03797.x"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.6.3373"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33559"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600126"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.03.041"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.456"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14071"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.12.029"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4790810"},{"key":"cit0036","volume":"8","author":"Yu H","year":"2019","journal-title":"Elife"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2047"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.10.006"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.01.016"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.005"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14550"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2013.05.006"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606490"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.03.018"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.013"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908316"},{"key":"cit0048","unstructured":"Kiniksa pharmaceuticals L. Kiniksa announces Phase 2 clinical trial of vixarelimab (KPL-716) in prurigo nodularis meets efficacy endpoint; 2020 April 22 [cited 2020 May 21]. Available from: https:\/\/investors.kiniksa.com\/events\/event-details\/kiniksa-announces-phase-2-clinical-trial-vixarelimab-kpl-716-prurigo-nodularis"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"cit0050","unstructured":"Park B Tralokinumab Safe, Effective in Phase 3 atopic dermatitis trials; 2019 December 12 [cited 2020 May 21]. Available from: https:\/\/www.empr.com\/home\/news\/drugs-in-the-pipeline\/tralokinumab-safe-effective-in-phase-3-atopic-dermatitis-trials\/"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.017"},{"key":"cit0052","unstructured":"Review PB Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis; 2019 December 11 [cited 2020 May 20]. Available from: https:\/\/www.pharmaceutical-business-review.com\/news\/dermira-lebrikizumab-fda-fast-track\/"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.016"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142898"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.059"},{"key":"cit0056","unstructured":"AnaptysBio. AnaptysBio reports etokimab atlas phase 2b clinical trial in moderate-to-severe atopic dermatitis fails to meet primary endpoint; [cited 2020 Jul 14]. Available from: https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptysbio-reports-etokimab-atlas-phase-2b-clinical-trial"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.053"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14313"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12400"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900408"},{"key":"cit0061","unstructured":"Pfizer announces positive top line results from second pivotal phase 3 study of investigational oral JAK1 candidate, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis 2019; 2019 September 27 [cited 2020 May 21]; Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_announces_positive_top_line_results_from_second_pivotal_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"cit0063","unstructured":"Pfizer announces positive top-line results from thrid phase 3 trial of abrocitinib for moderate to severe atopic dermatitis, which showed improvements in skin clearance, disease extent and severity, and itch; 2020 March 18 [cited 2020 May 21]. Available from: https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2020\/Pfizer-Announces-Positive-Top-Line-Results-from-Third-Phase-3-Trial-of-Abrocitinib-for-Moderate-to-Severe-Atopic-Dermatitis-Which-Showed-Improvements-in-Skin-Clearance-Disease-Extent-and-Severity-and-Itch\/default.aspx"},{"key":"cit0064","unstructured":"Pfizer receives breakthrough therapy designation from FDA for PF-04965842, an oral JAK1 inhibitor, for the treatment of patients with moderate to severe atopic dermatitis; 2018 [cited 2020 May 21]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_04965842_an_oral_jak1_inhibitor_for_the_treatment_of_patients_with_moderate_to_severe_atopic_dermatitis"},{"key":"cit0065","unstructured":"PharmaIntelligence. Abrocitinib; [cited 2020 May 21]. Available from: https:\/\/pharmaintelligence.informa.com\/products-and-services\/data-and-analysis\/pharmaprojects"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-014-0782-9"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.015"},{"key":"cit0071","author":"Worm M","journal-title":"Br J Dermatol"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.009"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3120"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2852"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2510"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.030"},{"key":"cit0078","unstructured":"Menlo therapeutics\u2019 serlopitant granted breakthrough therapy designation by FDA for the treatment of pruritus associated with prurigo nodularis; 2019 Jan 15 [cited 2020 May 20]. Available from: https:\/\/www.globenewswire.com\/news-release\/2019\/01\/15\/1691693\/0\/en\/Menlo-Therapeutics-Serlopitant-Granted-Breakthrough-Therapy-Designation-by-FDA-for-the-Treatment-of-Pruritus-Associated-with-Prurigo-Nodularis.html"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.056"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.052"},{"key":"cit0081","author":"Chiou AS","journal-title":"J Am Acad Dermatol"},{"key":"cit0082","unstructured":"Menlo therapeutics announces results from two phase 3 clinical trials of serlopitant for the treatment of pruritus associated with prurigo nodularis; 2020 April 6 [cited 2020 May 20]. Available from: http:\/\/ir.menlotherapeutics.com\/news-releases\/news-release-details\/menlo-therapeutics-announces-results-two-phase-3-clinical-trials"},{"key":"cit0083","unstructured":"Menlo therapeutics announces results from phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin; 2020 Feb 26 [cited 2020 May 21]. Available from: http:\/\/www.menlotherapeutics.com\/newsroom\/menlo-therapeutics-announces-results-from-phase-2-trial-of-serlopitant-in-patients-with-chronic-pruritus-of-unknown-origin\/"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.1184"},{"key":"cit0085","unstructured":"Vanda reports results from the EPIONE study of tradipitant in the treatment of pruritus in atopic dermatitis; 2020 February 25 [cited 2020 May 20]. Available from: https:\/\/www.prnewswire.com\/news-releases\/vanda-reports-results-from-the-epione-study-of-tradipitant-in-the-treatment-of-pruritus-in-atopic-dermatitis-301011169.html"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912770"},{"key":"cit0087","unstructured":"Cara receives breakthrough therapy designation from FDA for I.V. CR845 for the treatment of chronic kidney disease-associated pruritus in hemodialysis patients; 2017 June 23 [cited 2020 May 20]. Available from: http:\/\/ir.caratherapeutics.com\/news-releases\/news-release-details\/cara-receives-breakthrough-therapy-designation-fda-iv-cr845"},{"key":"cit0088","unstructured":"Cara therapeutics announces positive results from KALM-1 Pivotal Phase 3 trial of KORSUVA\u2122 injection in hemodialysis patients with pruritus; 2019 May 29 [cited 2020 May 20]. Available from: http:\/\/ir.caratherapeutics.com\/news-releases\/news-release-details\/cara-therapeutics-announces-positive-results-kalm-1-pivotal"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700942"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1159\/000484573"},{"key":"cit0091","unstructured":"Trevi therapeutics announces positive results from phase 2 trial in prurigo nodularis; 2016 October 13 [cited 2020 May 20]. Available from: https:\/\/www.trevitherapeutics.com\/wp-content\/uploads\/2019\/01\/TreviPNToplineDataPR.10_.13_.16_.FINAL_.pdf"},{"key":"cit0092","unstructured":"Sienna biopharmaceuticals announces its topical, non-steroidal TrkA inhibitor SNA-120 (0.05%) demonstrated significant impact on psoriasis in phase 2b study and plans to initiate phase 3 psoriasis trials in second half of 2019; 2018 December 3 [cited 2020 May 20]. Available from: https:\/\/investors.siennabio.com\/news-releases\/news-release-details\/sienna-biopharmaceuticals-announces-its-topical-non-steroidal"},{"key":"cit0093","unstructured":"Sienna biopharmaceuticals reports fourth quarter and full year 2018 financial results; 2019 March 14 [cited 2020 May 20]. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1656328\/000119312519074151\/d718739dex991.htm"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.001"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13231"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1397626"},{"key":"cit0097","unstructured":"Topical roflumilast cream ARQ 151 clinical development; [cited 2020 May 20]. Available from: https:\/\/arcutis.com\/trial\/arq-151\/"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12726"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.07.047"},{"issue":"8","key":"cit0100","first-page":"873","volume":"17","author":"Frankel E","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25214-0"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30319-7"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1305"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.004"},{"key":"cit0105","unstructured":"What is the list price of DUPIXENT? 2019 November [cited 2020 May 20]. Available from: https:\/\/www.dupixent.com\/dupixent-pricing"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1466022"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.3310\/hta21640"},{"issue":"13","key":"cit0108","first-page":"S439","volume":"22","author":"McCamish M","year":"2016","journal-title":"Am J Manag Care"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2020.1801632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T06:42:31Z","timestamp":1620456151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2020.1801632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7,2]]}},"alternative-id":["10.1080\/14728214.2020.1801632"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2020.1801632","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}